Cirsium Biosciences is pioneering a novel approach to gene therapy manufacturing by utilizing whole plants as bioreactors for the production of adeno-associated virus (AAV) vectors. This innovative platform addresses significant challenges in the current manufacturing landscape, such as inadequate production capacity, poor scalability, and high costs associated with clinical-grade manufacturing. By employing a linear scale-out production model, Cirsium's technology allows for rapid and reproducible scaling without extensive process development, achieving up to a 70% reduction in manufacturing lead times. This expedited process not only enhances access to vital gene therapies for patients but also simplifies the supply chain and minimizes batch failures through the use of a human pathogen-resistant platform.

The company's production methodology leverages transient gene delivery and high-density Controlled Environment Agriculture (CEA) to manufacture high-quality AAV vectors efficiently. Cirsium's process encompasses several key stages, including transformation, infiltration, and extraction, which are designed to optimize both upstream and downstream production. The entire manufacturing cycle is significantly faster than traditional methods, with critical steps completed in a matter of weeks. This streamlined approach not only ensures high-quality output but also results in substantial cost savings compared to conventional cGMP facilities, making gene therapy more accessible and affordable.

United States

Cirsium Biosciences is democratizing gene therapy through transformative viral vector production methods and systems.

Cirsium Biosciences

Company Details